贝那普利氢氯噻嗪片基层临床应用全科专家共识

2021-02-05 中国医师协会全科医师分会 中国全科医学.2021,24(11):1309-1316,1324.

固定配比的单片复方制剂已被证明可提高高血压患者治疗的依从性和血压控制率、改善患者预后。贝那普利氢氯噻嗪片用于治疗高血压已在国内外应用多年,积累了大量临床应用证据和经验,在基层高血压的治疗和管理中起到了

中文标题:

贝那普利氢氯噻嗪片基层临床应用全科专家共识

发布日期:

2021-02-05

简要介绍:

固定配比的单片复方制剂已被证明可提高高血压患者治疗的依从性和血压控制率、改善患者预后。贝那普利氢氯噻嗪片用于治疗高血压已在国内外应用多年,积累了大量临床应用证据和经验,在基层高血压的治疗和管理中起到了积极作用,但目前基层全科医生在临床应用时尤其是对于含氢氯噻嗪成分药物的应用仍存在一些疑虑,导致应用不足现象比较严重。为进一步加强和指导基层全科医生认识并合理应用贝那普利氢氯噻嗪片,促进高血压在基层的规范化管理,中国医师协会全科医师分会特组织相关领域专家组成专家共识组,基于最新的高质量循证证据和国内外相关指南制定本共识,主要内容包括贝那普利氢氯噻嗪片的特点和临床获益、在高血压及高血压合并其他疾病中的临床应用和基层应用要点,以期指导基层全科医生合理规范化应用贝那普利氢氯噻嗪片。

 

相关资料下载:
[AttachmentFileName(sort=1, fileName=贝那普利氢氯噻嗪片基层临床应用全科专家共识_马力.pdf)] GetToolGuiderByIdResponse(projectId=1, id=c68cb1c0020638bc, title=贝那普利氢氯噻嗪片基层临床应用全科专家共识, enTitle=, guiderFrom=中国全科医学.2021,24(11):1309-1316,1324., authorId=0, author=, summary=固定配比的单片复方制剂已被证明可提高高血压患者治疗的依从性和血压控制率、改善患者预后。贝那普利氢氯噻嗪片用于治疗高血压已在国内外应用多年,积累了大量临床应用证据和经验,在基层高血压的治疗和管理中起到了, cover=https://img.medsci.cn/2021223/1614011241977_2020535.jpg, journalId=0, articlesId=null, associationId=1581, associationName=中国医师协会全科医师分会, associationIntro= , copyright=0, guiderPublishedTime=Fri Feb 05 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>固定配比的单片复方制剂已被证明可提高高血压患者治疗的依从性和血压控制率、改善患者预后。贝那普利氢氯噻嗪片用于治疗高血压已在国内外应用多年,积累了大量临床应用证据和经验,在基层高血压的治疗和管理中起到了积极作用,但目前基层全科医生在临床应用时尤其是对于含氢氯噻嗪成分药物的应用仍存在一些疑虑,导致应用不足现象比较严重。为进一步加强和指导基层全科医生认识并合理应用贝那普利氢氯噻嗪片,促进高血压在基层的规范化管理,中国医师协会全科医师分会特组织相关领域专家组成专家共识组,基于最新的高质量循证证据和国内外相关指南制定本共识,主要内容包括贝那普利氢氯噻嗪片的特点和临床获益、在高血压及高血压合并其他疾病中的临床应用和基层应用要点,以期指导基层全科医生合理规范化应用贝那普利氢氯噻嗪片。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=5869, tagName=氢氯噻嗪), TagDto(tagId=9324, tagName=贝那普利)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=5869, guiderKeyword=氢氯噻嗪, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1993, appHits=110, showAppHits=0, pcHits=374, showPcHits=1883, likes=1, shares=3, comments=8, approvalStatus=1, publishedTime=Tue Feb 23 00:55:10 CST 2021, publishedTimeString=2021-02-05, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=qiushida2, createdTime=Tue Feb 23 00:27:26 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Tue Jan 02 11:10:29 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=贝那普利氢氯噻嗪片基层临床应用全科专家共识_马力.pdf)])
贝那普利氢氯噻嗪片基层临床应用全科专家共识_马力.pdf
下载请点击:
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1193510, encodeId=aa701193510e0, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Tue Feb 15 10:20:23 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947146, encodeId=700894e1467e, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a3b2206084, createdName=120c5cb5m15暂无昵称, createdTime=Wed Mar 10 16:14:03 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947145, encodeId=4d9194e14566, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a3b2206084, createdName=120c5cb5m15暂无昵称, createdTime=Wed Mar 10 16:13:47 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945978, encodeId=c4949459e846, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=177b5465842, createdName=有猫名叫芝士酱, createdTime=Sat Mar 06 17:02:16 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945186, encodeId=5bcc94518659, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Mar 03 16:29:24 CST 2021, time=2021-03-03, status=1, ipAttribution=)]
    2022-02-15 光明骑士

    学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1193510, encodeId=aa701193510e0, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Tue Feb 15 10:20:23 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947146, encodeId=700894e1467e, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a3b2206084, createdName=120c5cb5m15暂无昵称, createdTime=Wed Mar 10 16:14:03 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947145, encodeId=4d9194e14566, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a3b2206084, createdName=120c5cb5m15暂无昵称, createdTime=Wed Mar 10 16:13:47 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945978, encodeId=c4949459e846, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=177b5465842, createdName=有猫名叫芝士酱, createdTime=Sat Mar 06 17:02:16 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945186, encodeId=5bcc94518659, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Mar 03 16:29:24 CST 2021, time=2021-03-03, status=1, ipAttribution=)]
    2021-03-10 120c5cb5m15暂无昵称

    感谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1193510, encodeId=aa701193510e0, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Tue Feb 15 10:20:23 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947146, encodeId=700894e1467e, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a3b2206084, createdName=120c5cb5m15暂无昵称, createdTime=Wed Mar 10 16:14:03 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947145, encodeId=4d9194e14566, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a3b2206084, createdName=120c5cb5m15暂无昵称, createdTime=Wed Mar 10 16:13:47 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945978, encodeId=c4949459e846, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=177b5465842, createdName=有猫名叫芝士酱, createdTime=Sat Mar 06 17:02:16 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945186, encodeId=5bcc94518659, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Mar 03 16:29:24 CST 2021, time=2021-03-03, status=1, ipAttribution=)]
    2021-03-10 120c5cb5m15暂无昵称

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1193510, encodeId=aa701193510e0, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Tue Feb 15 10:20:23 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947146, encodeId=700894e1467e, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a3b2206084, createdName=120c5cb5m15暂无昵称, createdTime=Wed Mar 10 16:14:03 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947145, encodeId=4d9194e14566, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a3b2206084, createdName=120c5cb5m15暂无昵称, createdTime=Wed Mar 10 16:13:47 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945978, encodeId=c4949459e846, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=177b5465842, createdName=有猫名叫芝士酱, createdTime=Sat Mar 06 17:02:16 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945186, encodeId=5bcc94518659, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Mar 03 16:29:24 CST 2021, time=2021-03-03, status=1, ipAttribution=)]
    2021-03-06 有猫名叫芝士酱

    学习

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1193510, encodeId=aa701193510e0, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4d585243593, createdName=光明骑士, createdTime=Tue Feb 15 10:20:23 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947146, encodeId=700894e1467e, content=感谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=89, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a3b2206084, createdName=120c5cb5m15暂无昵称, createdTime=Wed Mar 10 16:14:03 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=947145, encodeId=4d9194e14566, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=80, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7a3b2206084, createdName=120c5cb5m15暂无昵称, createdTime=Wed Mar 10 16:13:47 CST 2021, time=2021-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945978, encodeId=c4949459e846, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=177b5465842, createdName=有猫名叫芝士酱, createdTime=Sat Mar 06 17:02:16 CST 2021, time=2021-03-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=945186, encodeId=5bcc94518659, content=好共识!, beContent=null, objectType=guider, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160806/IMG57A5698BDB0244113.jpg, createdBy=32a91358059, createdName=jyzxjiangqin, createdTime=Wed Mar 03 16:29:24 CST 2021, time=2021-03-03, status=1, ipAttribution=)]
    2021-03-03 jyzxjiangqin

    好共识!

    0

拓展阅读

2019 BIHS科学声明:氢氯噻嗪和皮肤癌风险

英国和爱尔兰高血压学会(BIHS,British and Irish Hypertension Society) · 2019-03-06